In Brief
Modified CAR-T cells can be used as in vivo micro-pharmacies for local delivery of HVEM, a soluble tumor suppressor protein that is active against lymphoma.
SUMMARY
The HVEM (TNFRSF14) receptor gene is among the most frequently mutated genes in germinal center lymphomas. We report that loss of HVEM leads to cell-autonomous activation of B cell proliferation and drives the development of GC lymphomas in vivo. HVEM-deficient lymphoma B cells also induce a tumor-supportive microenvironment marked by exacerbated lymphoid stroma activation and increased recruitment of T follicular helper (T FH ) cells. These changes result from the disruption of inhibitory cell-cell interactions between the HVEM and BTLA (B and T lymphocyte attenuator) receptors. Accordingly, administration of the HVEM ectodomain protein ) binds BTLA and restores tumor suppression. To deliver solHVEM to lymphomas in vivo, we engineered CD19-targeted chimeric antigen receptor (CAR) T cells that produce solHVEM locally and continuously. These modified CAR-T cells show enhanced therapeutic activity against xenografted lymphomas. Hence, the HVEM-BTLA axis opposes lymphoma development, and our study illustrates the use of CAR-T cells as ''micro-pharmacies'' able to deliver an anti-cancer protein.
INTRODUCTION
Most human lymphomas arise from germinal center (GC) B cells. These include diffuse large B cell lymphomas (DLBCLs) and follicular lymphomas (FLs), which continue to pose a significant health challenge. Recent genomic studies have yielded important new insight into lymphoma pathogenesis and have cataloged recurrent genomic lesions (Challa-Malladi et al., 2011; Cheung et al., 2010; Lohr et al., 2012; Morin et al., 2011; Okosun et al., 2014; Oricchio et al., 2011; Pasqualucci et al., 2014) . In addition, the germinal center (GC) microenvironment has been discussed as a key factor in lymphoma development and as a predictor of clinical outcomes (Amé -Thomas et al., 2007; Amin et al., 2015; Dave et al., 2004; Lenz et al., 2008; Mourcin et al., 2012; Pangault et al., 2010) . However, precise mechanisms linking the GC microenvironment to the pathogenesis of GC lymphomas are largely unknown.
The GC microenvironment is critical for most aspects of B cell function and likely contributes to lymphomagenesis. GCs are dynamic structures that are composed of multiple hematopoietic and stromal cell types (Chang and Turley, 2015; De Silva and Klein, 2015) . For example, the main lymphoid stromal cell subtypes, fibroblastic reticular cells (FRCs) and follicular dendritic cells (FDCs), contribute to B cell recruitment, survival, and differentiation (Aguzzi et al., 2014; Fletcher et al., 2015) . In turn, activated B cells produce the tumor necrosis factor (TNF) family cytokines TNF-a and LTa1b2 that stimulate FRCs and FDCs (Roozendaal and Mebius, 2011) . CXCL13 derived from these stromal cells is the major attractant for follicular T helper (T FH ) cells that, in turn, support B cells through CD40L and secretion of cytokines interleukin 4 (IL-4) and IL-21 (Crotty, 2014) . Especially, FL B cells retain a strong dependence on the GC microenvironment, which is thought to form a permissive niche and engage in crosstalk with malignant B cells (Amé - Thomas and Tarte, 2014; Mourcin et al., 2012; Rehm et al., 2011) .
Cancer-specific gene alterations can shed light on tumor biology. For example, somatic mutations in the HVEM (Herpes Virus Entry Mediator; TNFRSF14) receptor gene are among the most frequent genetic lesions in GC lymphomas and have been variably associated with prognosis (Cheung et al., 2010; Launay et al., 2012; Lohr et al., 2012) . Exactly how HVEM mutations contribute to the biology of GC lymphomas is not known.
Studies of the HVEM receptor in T lymphocytes inform our current knowledge of this receptor's function. In T lymphocytes HVEM engages in stimulating cell-cell interactions by binding to LIGHT or CD160 receptors, whereas HVEM binding to the BTLA receptor (B and T lymphocyte attenuator) results in an inhibitory signal (Bjordahl et al., 2013; Cai and Freeman, 2009; Costello et al., 2003; Pasero et al., 2012; Steinberg et al., 2011) . Expression of HVEM and its partner receptors is lineage restricted. For example, normal B cells variably express HVEM and BTLA depending on their differentiation and activation stage but they lack LIGHT and CD160, whereas T FH cells are characterized by their high BTLA expression (M'Hidi et al., 2009; Murphy et al., 2006) .
Our study examines the function of HVEM in GC lymphomagenesis using a genetically and pathologically accurate mouse model. We further explore strategies to restore HVEM function by delivering the HVEM ectodomain (solHVEM ) to lymphomas in vivo.
RESULTS

The Interaction between the HVEM and BTLA Receptors Is Lost in Most Human FLs
In a large collection (n = 141) of human FLs, we find HVEM mutations in 28% (n = 40), and one-third (35%) of these are homozygous mutations ( Figures 1A-1C ) (Cheung et al., 2010; Launay et al., 2012; Lohr et al., 2012; Ross et al., 2007) . HVEM mutations target the receptor's ectodomain and include missense (65%), nonsense (32.5%), and frameshift mutations (2.5%). Moreover, HVEM localizes to the minimal common region of the chromosome 1p36 deletion-a region that is commonly lost across B cell malignancies (Cheung et al., 2010; Fitzgibbon et al., 2007; Martin-Guerrero et al., 2013) . Our meta-analysis of two separate series of array comparative genomic hybridization (CGH) data Memorial Sloan-Kettering Cancer Center (MSKCC): n = 64 (Oricchio et al., 2011) ; University of Nebraska Medical Center (UNMC) cohort: n = 198 (Bouska et al., 2014) shows that loss of the HVEM locus occurs in 34% of indolent FL samples (n = 262), and 37% of transformed FLs (n = 67) ( Figures 1D-1F , S1A, and S1B). Genomic identification of significant targets in cancer (GISTIC) analysis indicates that 22%-24% of these lesions are homozygous losses in both indolent and transformed samples ( Figures 1E and S1A) . Hence, the genomic evidence indicates a powerful selection against the HVEM receptor gene during FL development.
We also examined HVEM protein expression in human FLs. We evaluated tissue microarrays comprising 198 FL samples for HVEM protein expression by immunohistochemistry. We scored a sample as HVEM positive when at least 20% of tumor cells showed specific staining. Using this cutoff, 61 samples (31.3%) were HVEM negative, and 135 samples (68.7%) were classified as HVEM positive ( Figures 1G and S1C ). This proportion is consistent with the genomic data, and we confirm reduced or absent protein expression in HVEM mutated or deleted samples for samples (n = 14) with available genomic and protein data ( Figure S1D ).
BTLA is a known HVEM binding partner and the only HVEM receptor expressed on normal and FL B cells (Murphy et al., 2006) . Therefore, we evaluated BTLA expression across the lymphoma tissue arrays. For a positive BTLA score, we demanded that tumor cells showed a stronger stain than reactive GC B cells, which are weakly positive and were used as on-slide controls. Using this cutoff for BTLA, 102 samples were negative (51.2%), and 94 samples (48.2%) scored as positive (Figures 1G and S1E) . Together, 145 of 198 samples (73%) were negative for either HVEM or BTLA, and we wondered whether these events might be linked. We tested their association using the chi-square and found a significant negative (mutual exclusive) association such that HVEM positive tumors were more likely to lose BTLA than expected by chance (OR = 0.254; 95% CI 0.126-0.511; p < 0.0001) ( Figures 1G-1I , S1F, and S1G). We did not observe mutations or deletions of BTLA, and it is most likely silenced transcriptionally. In this regard, we notice that BTLA expression is controlled by the KMT2D (MLL2) methyltransferase in FL (Ortega-Molina et al., 2015) . Hence, the interaction between the HVEM and BTLA receptors is disrupted in the majority of human FLs indicating a potentially important tumor suppressor axis.
HVEM Acts as a Tumor Suppressor in a Mouse Model of Follicular Lymphoma
To elucidate the role of HVEM inactivation in FL development, we took advantage of the vavPBcl2 model that recapitulates key aspects of the genetics and pathology of human BCL2-positive FLs (Egle et al., 2004; Oricchio et al., 2011) . Briefly, we transduced vavPBcl2 hematopoietic progenitor cells (HPCs) isolated from fetal livers with retroviruses expressing short hairpin RNAs (shRNAs) against Hvem or empty vector controls. We then transplanted these cells into lethally irradiated mice and monitored the recipients for lymphoma development (Figure 2A ). Knockdown of Hvem (red, n = 19) caused a significant acceleration and increased penetrance of lymphoma development compared to controls (blue, n = 11). Ninety percent of control animals remained tumor free for >100 days compared to only 10% of animals receiving the shHvem (p < 0.01) ( Figure 2B ). We confirmed these results with a second shRNA against Hvem ( Figure S2A ). We also confirmed knockdown of the Hvem mRNA and Hvem surface expression by fluorescence-activated cell sorting (FACS) ( Figures 2C, 2D , and S2B). To test whether the HVEM knockdown in the B cell compartment was responsible for lymphoma development, we tracked the expression of the shHvem co-expressed with the GFP reporter from the initial HPC infection into the derived hematopoietic compartments and did the same with HPCs expressing empty vector and GFP. The initial transduction efficiencies of the HPCs were $15%, and we found enrichment only in the FACS shHvem-expressing lymphoma B cells (approximately 80%); by contrast, we saw no enrichment with empty vector and GFP-transduced HPCs (Figures 2E and S2C) . We noticed that the shHvem and GFP were also expressed but not enriched in a fraction of whole CD8 + and CD4 + T cells See also Figure S1 and Tables S1, S2 , S3, S4, and S5. See also Figure S2 and Figure 2F ). See also Figure S3 and Table S6 .
BLNK, and their downstream targets ERK and IkB in HVEM-deficient lymphomas compared to control lymphomas ( Figure 2G ). Deep sequencing-based BCR analysis revealed an oligoclonal disease and associated repertoire bias, with somatic hypermutation (SHM) yielding intraclonal diversity consistent with ongoing clonal evolution of a GCdriven disease ( Figure S3 ). In human FL samples, we had noticed a mutual exclusive pattern of HVEM and BTLA expression ( Figures 1G-1I ). Studies in T cells have indicated that HVEM and BTLA can directly interact on the same cell-in cis (Cheung et al., 2009) . These findings raise the possibility that loss of BTLA may similarly promote lymphoma development. We directly tested the effect of Btla knockdown in the same vavPBcl2 mouse lymphoma model. Briefly, Btla knockdown caused a significant acceleration of lymphoma development (n = 11 vector, n = 16 for Btla, p < 0.01) ( Figures 3A and 3B 
HVEM Controls Mitogenic Signals in a Cell-Autonomous and BTLA-Dependent Manner
We have seen that loss of HVEM and BTLA lead to BCR activation in murine lymphomas B cells (Figures 2G and 3F) . Activation of the BCR signal could be a direct effect related to BTLA's ability to bind CD79, or alternatively it could be secondary to changes in local cytokine levels (Vendel et al., 2009) . In order to test whether HVEM has a direct, cell-autonomous, and BTLA-dependent effect on signaling, we treated isolated lymphoma B cells with a purified soluble HVEM ectodomain protein fragment (solHVEM: Pro37 to Val202) that retains HVEM's binding properties (Cheung et al., 2005; del Rio et al., 2010) . Briefly, we stimulated the BCR signaling pathway in Bcl1mouse lymphoma cells with anti-immunoglobulin M (IgM) in the presence or absence of solHVEM (10 mg/ml) or the pharmacological BTK inhibitor ibrutinib (10 nM) and measured BTK phosphorylation as an indicator of BCR pathway activation by flow cytometry. The addition of sol-HVEM blocked BTK phosphorylation and activation similar to the pharmacological inhibitor ( Figure 4A ). The ability of solHVEM to block the BCR signal transduction required BTLA and knockdown of BTLA prevented BTK inhibition in Bcl1 cells ( Figure 4B ). We made similar observations in primary human FL B cells. First, we stimulated purified human FL B cells with anti-IgG in the presence or absence of solHVEM (TNFRSF14; 10 mg/ml) or the unrelated ectodomain of TNFRSF18 (10 mg/ml) and confirmed HVEM-specific inhibition of pSYK, pBLNK, and pERK (Figure 4C) . Next, we analyzed BTLA expression across ten samples of purified human FL B cells by FACS and divided them into BTLA hi and BTLA lo groups ( Figure 4D ). We treated them as above and observed inhibition of SYK and ERK in BTLA hi cells, whereas solHVEM had little effect in the BTLA lo cells ( Figure 4E ).
Cumulative analysis of all ten primary human FL B cells confirmed a significant relationship between the ability of sol-HVEM to block SYK phosphorylation and BTLA surface expression (r = 0.697, p = 0.03) ( Figure S4A ). We further confirmed solHVEM's (10 mg/ml) inhibitory effect on BTK, SYK, and ERK phosphorylation in DoHH2 lymphoma cells that express BTLA and carry a homozygous HVEM deletion ( Figures S4B-S4F) . reticular cells (FRCs) (Roozendaal and Mebius, 2011 ). An analysis of cytokine production in purified B220 + B cells from HVEM-deficient lymphomas compared to control lymphomas revealed significantly increased production of all three stroma activating factors (n = 5, p < 0.05) ( Figure 5A ). Moreover, treatment of two different mouse lymphoma lines (Bcl1 and Myc/Bcl2) with the HVEM ectodomain (solHVEM; 10 mg/ml) significantly decreased the expression of LTa and LTb but did not change TNF-a (p < 0.05); and differential regulation of these cytokines has been attributed to STAT5 activation (Lauenborg et al., 2015) (Figures 5B-5D and S5B-S5D). The increased production of stroma activating TNF family cytokines was reflected in the abnormal lymphoid stroma activation in HVEM-deficient tumors (Figure 5E ). Quantitative analysis of microscopic images showed a significant increase of the CD21/CD35 pos FDC network within follicles in HVEM-deficient tumors compared to control tumors in the absence of immunization (n = 3; p < 0.01) ( Figure 5F ). Similarly, type I collagen density in perifollicular areas was significantly (p < 0.001) increased in HVEM-deficient lymphomas reflecting activation of FRCs (Figure 5G) . However, quantification of FRC branching did not reveal a quantitative increase in FRC cells and their network (Figures S5E and S5F) . Further, consistent with these microscopic indicators of lymphoid stroma activation we observed significantly elevated expression of FDC-and FRC-derived cytokines-CXCL13 and CCL19-in the HVEM-deficient tumors compared to controls (n = 5; p < 0.05) (Mueller and Germain, 2009) (Figures 5H and 5I) . Hence, HVEM deficiency contributes to the aberrant activation of lymphoid stroma cells.
Increased T FH Cells in HVEM-Deficient Lymphomas
The stroma-derived cytokine CXCL13 is the main chemo-attractant for CXCR5 pos follicular T helper cells (T FH ) (Crotty, 2014) .
Consistent with the increased CXCL13 production in HVEM-deficient lymphomas ( Figure 5H ), we observed a significant increase in the abundance of T FH cells in the HVEM-deficient compared to control tumors (n = 3; p < 0.01) ( Figures 6A and 6B ). This increase in T FH cell numbers is associated with an elevated expression of T FH -derived cytokines. Specifically, we find increased expression of IL-21, IL-4, and the stroma activating cytokines TNF-a, LTa, and LTb in FACS-purified CD3 + T cells from HVEM-deficient versus control lymphomas (n for each genotype = 5, p < 0.01) ( Figures 6C-6E ). These T FH changes were not caused by aberrant shHVEM expression or loss of HVEM in T FH cells (Figure S2E) . Intriguingly, we observed that the increased production of IL-21 and IL-4 by T FH cells was matched with an elevated expression of the IL-21 and IL-4 receptors on FACS purified lymphoma B cells from HVEM-deficient lymphomas (p < 0.01) ( Figures S6A and S6B ). Human T FH cells are characterized by high-level expression of the BTLA receptor ( Figure S6C ), and we wondered whether HVEM directly affected these tumor infiltrating T cells. In order to test the direct effect of HVEM on T FH cells, we treated purified human T FH cells with solHVEM as before in the presence or absence of stimulation with anti-CD3 and anti-CD28. SolHVEM did not affect T FH cell numbers or viability, and we observed reductions in the expression of LTa and LTb, but not of TNF-a, IL-21, or CXCL13 (Figures 6F-6H and S6D-S6F). Hence, genetically engineered murine HVEMdeficient lymphomas show an increased ability to recruit IL-4-and IL-21-producing T FH cells.
We wondered whether these changes might also be detectable in our collection of human FL samples. First, we measured T FH cell infiltration in relation to HVEM protein expression. We grouped all 198 tumors by high, medium, and low HVEM expression and quantified the percentage of PD1 hi T FH cells as a fraction of all CD4 T cells. This revealed a significant increase in T FH infiltration (p = 0.032; comparing high to medium to low HVEM by one-way ANOVA) ( Figure 6I ). The T FH -derived cytokine IL-4 activates STAT6 (Pangault et al., 2010) ; therefore, we examined STAT6 phosphorylation in tumors with >90% of HVEM positive B cells (n = 24) and those that were essentially HVEM negative (i.e., < 10% HVEM positive B cells; n = 59). Consistent with increased numbers of IL-4-producing T FH cells, we observed a significant increase in STAT6 phosphorylation in the HVEM negative FLs (p = 0.047) ( Figure 6J ). Hence, despite the genetic complexity of human FLs, we can detect significant differences in T FH recruitment and B cell activation in HVEM-deficient FLs.
The HVEM Ectodomain Protein Has Tumor Suppressive Effects
In order to test the potential anti-tumor effect of the solHVEM protein (HVEM Pro37-Val202 ), we first characterized the expression of HVEM and BTLA across a panel of human and mouse lymphoma (mostly DLBCL) cell lines ( Figure S7A ). SolHVEM caused a significant growth inhibition in all BTLA hi lymphoma cells, whereas vehicle or the unrelated TNFRSF18 protein had no effects. Consistent with our results in human FL samples and primary cells (Figures 1 and 4) , we found that BTLA lo cell lines generally expressed higher levels of HVEM and were insensitive to the solHVEM protein ( Figure S7B ). Next, we examined the activity of solHVEM against established lymphomas in vivo. We transplanted aggressive Myc/ Bcl2 double-positive murine lymphoma cells that express BTLA and lack HVEM (BTLA hi /HVEM lo ) into the flanks of J:Nu nude mice and initiated treatment with intra-tumoral injection of solHVEM or vehicle (PBS) every 3 days for a total of four times once the engrafted tumors reached a volume of $75 mm 3 . Treatment with the solHVEM protein (20 mg) prevented tumor growth, whereas the vehicle-treated tumors expanded rapidly (n = 4; p < 0.01) ( Figures 7A, 7B , S7C, and S7D). The effect of solHVEM was not merely cytostatic and TUNEL stains showed abundant apoptosis and immunoblots indicated ERK inhibition in vivo (Figures 7C and 7D) . We also tested systemic injection of solHVEM (100 mg, i.v.) in Myc/Bcl2 murine lymphomas and observed only a modest effect (n = 5; p = 0.12) ( Figure S7E ). These results indicate the powerful biological activity of solHVEM, and they also highlight the need to achieve an adequate local exposure.
CAR-T Cells Can Produce and Secrete the solHVEM Tumor Suppressor
We engineered chimeric antigen receptor (CAR) T cells that seek out CD19-expressing B cells and that locally and continuously produce the solHVEM protein. Briefly, building on the reported CD19 CAR construct (Brentjens et al., 2013) we introduced the solHVEM coding sequence under separate transcriptional control and preceded by a secretion signal along with the GFP reporter for ease of tracking ( Figure 7E ). We confirmed that our CAR-T/solHVEM cells expressed and secreted the solHVEM protein by western blot on CAR-T lysates and by ELISA on CAR-T supernatants, respectively ( Figures 7F and 7G ). Initial tests showed that the solHVEM did not decrease T cell viability or impair CD3-and CD28-mediated T cell activation ( Figures  S7G and S7H ). Next, we compared the ability of CAR-T and CAR-T/solHVEM cells to kill DoHH2 lymphoma cells in vitro and observed a significant enhancement in cell killing with CAR-T/solHVEM after 24 hr co-culture ( Figure S7I ). We tested the in vivo efficacy of CAR-T cells against xenografted DoHH2 lymphomas and treated lymphoma-bearing animals (tumor >25 mm 3 ) with a single intravenous injection of 1 3 10 5 CAR-T cells. We compared CAR-T cells directed against an unrelated prostate antigen (4H11), regular CD19-directed CAR-T cells (CD19), and the HVEM-producing and CD19-targeted CAR-T cells (CD19/solHVEM). We observed no frank toxicity or mortality with a single injection of CAR-T cells in either group (data not shown). Compared to the control CAR-T (4H11) cells, both the CD19-CAR-T cells and the solHVEM-producing CAR-T cells produced significant therapeutic responses (n = 15; p < 0.05 for both comparisons). Moreover, the CAR-T/ solHVEM cells were significantly more effective than the current CD-19 directed CAR-T cells (p = 0.016) (Figures 7H and 7I) . The GC is the origin of most human B cell lymphomas, and our study provides new insight into their pathogenesis. We find that the HVEM-BTLA interaction is disrupted in 75% of FLs indicating that it is a critical barrier to lymphoma development. The HVEM receptor gene is among the most frequent genetic targets in lymphomas, and somatic mutations and chromosomal deletions typically result in loss of the receptor, and some mutations may affect specific functions. BTLA is the only HVEM-interacting receptor expressed in normal and GC lymphoma B cells and lymphomas that retain wild-type HVEM are likely to silence expression of the BTLA receptor gene. BTLA is not a target of mutations or deletions; instead, we notice that BTLA is a target of the KMT2D (MLL2) histone methyltransferase and KMT2D inactivation in lymphomas may contribute to silencing BTLA expression (Ortega-Molina et al., 2015) . The high prevalence of these changes and the fact that they do not increase in transformed FLs suggests that the HVEM-BTLA axis is a failsafe mechanism that is disrupted during the early stages of GC lymphomagenesis.
Cell-Autonomous and Microenvironmental Consequences of HVEM Loss
Our findings indicate that HVEM inactivation has dual effects on the lymphoma B cells and also shapes a tumor-supportive niche. First, loss of HVEM stimulates BCR signaling and B cell growth in a cell-autonomous and strictly BTLA-dependent manner. The inhibitory BTLA receptor has two ITIM domains that can interact with BCR signaling molecules (CD79, SHP1/2) Vendel et al., 2009; Watanabe et al., 2003) . Stimulation of BTLA by cell-surface HVEM or soluble HVEM leads to inhibition of BCR signaling molecules and blocks lymphoma cell proliferation. In T cells, this interaction can occur in cis on the same cell (Cheung et al., 2009 ). In B cell lymphomas this interaction may occur in cis leading to cell-autonomous growth inhibition and also in trans, which would resemble a form of contact inhibition. Either way, disruption of the HVEM-BTLA interaction provides a mechanism of activating BCR related mitogenic signals in lymphoma B cells. HVEM loss results in microenvironmental changes that support lymphoma growth. HVEM-deficient B lymphocytes produce increased amounts of TNF family cytokines (TNF-a, LTa, LTb that are the key activators of lymphoid stroma cells such as FDCs and FRCs [Amé - Thomas et al., 2007; Guilloton et al., 2012; Roozendaal and Mebius, 2011] ). The activated lymphoid stroma in HVEM-deficient mouse lymphomas closely resembles the abnormal stroma activation seen in human FLs (Mourcin et al., 2012) . Human FL B cells show a unique dependence on stromal support that is mediated, at least in part, through increased CCL19 and CXCL13-mediated recruitment of T FH cells that, in turn, support B cells by producing IL-4, IL-21, and CD40L (Amé - Thomas et al., , 2015 Pangault et al., 2010) . These changes are readily evident in the genetically engineered mouse lymphomas, and we find activation of this supportive niche with increased T FH cells and IL-4 signaling also in human HVEMdeficient FLs.
Direct and Knockon Effects of HVEM Loss
HVEM produces direct and BTLA-dependent effects on B and T FH cells; in addition, we observe secondary changes due to altered cytokine production. For example, lymphoid stromal cells do not express BTLA (data not shown) and effects on the lymphoid stroma are mostly secondary to increased production of TNF family cytokines. On the other hand, BTLA is present at very high levels on T FH cells. Accordingly, we have seen that T FH cells are subject to both increased CXCL13-mediated recruitment and also direct effects of HVEM on T FH cells. Similarly, HVEM directly engages BTLA on lymphoma B cells, and in addition T FH -derived cytokines such as IL-4 and IL-21 provide further support for B cell growth. Likely, HVEM has additional consequences, and our study highlights how loss of HVEM disrupts a critical node that controls B cell growth in the GC environment.
Restoring the HVEM-BTLA Interaction for Therapy HVEM is one of the most frequently mutated genes in FL and DLBCL, and a therapeutic strategy tailored to HVEM-deficient lymphomas is desirable. Notably, the interactions between the tumor suppressive HVEM and BTLA receptors occur at the cell surface and are, in principle, accessible for therapeutic attack. A soluble HVEM ectodomain protein (solHVEM) activates the inhibitory BTLA receptor resulting in impaired BCR signaling, partial normalization of cytokine production, apoptosis, and tumor growth delay in vivo. However, this approach has two limitations. First, the anti-tumor effects of solHVEM depend on BTLA expression, and an alternate strategy is needed to treat BTLAdeficient lymphomas. Second, delivery of solHVEM to the lymphomas is challenging and may be achieved with bi-specific antibodies as we showed in Oricchio et al. (2011) , or alternatively by engineering HVEM-producing cells as a vehicle.
CAR-T Cells as ''Micro-pharmacies'' to Dispense solHVEM
There is much excitement about the use of genetically engineered CAR-T cells that can, in principle, attack any tumor antigen (Batlevi et al., 2016; Brentjens et al., 2003) . Indeed, this approach has shown impressive results especially against CD19 + B cell leukemias; however, they appear to be less effective against lymphomas (Sadelain et al., 2015) . To enhance the anti-lymphoma activity of CAR-T cells, we have engineered CD19-directed CAR-T cells to produce and secrete the solHVEM tumor suppressor protein. Given HVEM's biological activity and the high frequency of HVEM inactivation in FL and DLBCL, we reasoned that local and continuous production would be superior to other forms of systemic delivery and may reduce unwanted off-target effects. Our findings indicate enhanced anti-lymphoma activity of solHVEM-producing CAR-T cells. They provide proof of concept for the use of engineered immune cells as targeted delivery vehicles or ''micro-pharmacies.'' Additional studies are warranted to enhance the specific delivery of BTLA activating factors to HVEM-deficient lymphomas and to explore cell-engineering technology as a platform for therapeutic delivery.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Generation of Mice All mice were housed in the specific-pathogen-free animal facility at the Memorial Sloan Kettering Cancer center and all animal studies were approved by the MSKCC IACUC committee (protocol-07-01-002). Unless indicated all mice studies used female mice on the C57Bl/6J background that were between 6 and 10 weeks of age. Wild-type mice were obtained from Jackson Laboratory (Bar Harbor, ME).
The vavPBcl2 mouse model is described (Egle et al., 2004) and adapted to adoptive transfer to retrovirally transduced HPCs . In summary, we isolated vavPBcl2 transgenic fetal liver cells from vavPBcl2 heterozygous animals at embryonic day 14.5 (E14.5). The HPCs were grown in vitro for 4 days in a specially adapted growth medium containing IL3, stem cell factor, and IL6 and are retrovirally transduced with MSCV vectors directing the expression of shRNAs of interest. We transplant the genetically modified HPCs into lethally irradiated, syngeneic wild-type recipients and monitor disease onset weekly by palpation. cells with a purity greater than 98% as described (Mourcin et al., 2012; Pangault et al., 2010) . Primary FL B cells were purified using the B cell isolation kit II (Miltenyi Biotech). Antibodies used in staining: Miltenyi CD3 (clone BW264/56), Beckman Coulter CD4 (clone 13B8.2), eBiosciences PD-1 (clone J105), and BD Biosciences CD25 (clone M-A251), CXCR5 (RF8B2), and BTLA (clone J168-540).
Human Samples
METHOD DETAILS
Exon Sequencing of HVEM Primers to amplify and sequence all coding exons and adjacent intronic sequences of HVEM were designed using the primer 3 program (http://primer3.ut.ee/) and sequence information generated using direct sequencing as described. Mutations were confirmed to be somatically acquired using unamplified lymphoma cell-derived DNA and paired CD3 cell-derived DNA from sorted cells as templates. (Li et al., 2014; Yildiz et al., 2015) .
Deep Coverage Massively Parallel Re-Sequencing of HVEM A customized multiplexed primer panel (QIAGEN Gene Read Panel) was used to amplify all coding exons of HVEM. PCR products were pooled and sequencing libraries prepared using barcoded adapters. Sequencing was done on a HiSeq2000 sequencer. Bioinformatics nomination of sequence variants was performed using a custom algorithm developed by the University of Michigan bioinformatics core. Fastq files were uploaded to the QIAGEN GeneRead data portal (http://ngsdataanalysis.sabiosciences.com/NGS2/) to trim primer regions from the reads and to align to the human genome (build hg19) using bowtie26. The aligned bam files were individually downloaded from the QIAGEN portal and submitted to VarScan (2.3.6) for variant calling with default parameters. SnpEff (3.4B) was used to annotate the variants with gene names and predicted impact on amino acid sequence; dbNSFP (2.1) was used to annotate predicted functional impact based on standard tools (Sift, Polyphen, MutationTaster). Variants found in 1000 Genomes phase 2 were excluded9. Jacquard, a custom tool developed by the UM Bioinformatics Core, was used to combine all sample VCFs into a single matrix of variants by samples. All sequence variants with VAF > 15% were validated in stock T and paired N DNA using Sanger sequencing.
Array-CGH and Gistic Analysis DNA from fresh frozen tissue or OCT-embedded was isolated and processed as previously described (Bouska et al., 2014; Oricchio et al., 2011) . In summary, labeling and hybridization was done according to protocols performed by Agilent Technologies. Before submission to the Genomics core for labeling and hybridization to the 244K oligonucleotide array (Agilent Technologies), digestion efficiency of each DNA was checked by incubating 1 kb DNA ladder. Human male DNA served as the reference DNA. The slides were scanned at 5-um resolution using the G2565 Microarray Scanner System (Agilent) and Feature Extraction software (v9.1; Agilent Technologies) was used to generate the data. The accession number for the raw data files reported in this paper is NCBI Gene Expression Omnibus: GSE40989. Copy Number Data from the second dataset that consisted of 197 follicular lymphoma patients (UNMC dataset) has been generated using GeneChip Human Mapping 250K Nsp SNP array (Affymetrix) as described in (Bouska et al., 2014) . To identify significantly amplified and deleted regions we used the Gistic 2.0 algorithm through the GenePattern web service (https:// genepattern.broadinstitute.org/gp/pages/login.jsf) (Oricchio et al., 2014) . GISTIC 2.0 (Beroukhim et al., 2010) has been run on segmented copy number data generated for each dataset using the DNAcopy package from Bioconductor (Olshen et al., 2004) .
Immunohistochemical and TMA Methods Immunohistochemistry (IHC) was applied to a tissue microarray (TMA) encompassing 1.5 mm duplicate cores of 199 formalin-fixed, paraffin-embedded (FFPE) tissue specimens from 186 patients diagnosed with FL (Kridel et al., 2015) 4 mm sections were cut and IHC was performed on a Ventana BenchMark XT platform (Ventana, AZ) using a mouse monoclonal antibody against HVEM (dilution 1:50; clone 2G6-2C7; Abnova, Walnut, CA) and a rabbit polyclonal antibody against CD272/BTLA (dilution 1:100; Epitomics, cat. # S2379; Toronto, ON). Slides were evaluated by two hematopathologists (AM and RDG) for the percentage of positive tumor cells (in 10% increments) and staining intensity (0 = negative, 1 = weak, 2 = moderate, 3 = strong). Representative images were acquired with a Nikon DS-Fi1 camera connected to a Nikon Eclipse E600 microscope. The following antibodies were used to examine composition and functional properties of the microenvironment in human FL specimens: CD4(neat, clone SP35, Roche Ventana), PD-1 (dilution 1:50, clone MRQ-22, ESBE Cell Marque), pSTAT-6 (dilution 1:100, clone 18/P-Stat6, BD Biosciences). Immunohistochemical stained slides for CD4 and PD-1 were scanned with an Aperio ScanScope XT at 20x magnification. Analysis was performed utilizing the Aperio ImageScope viewer (Version 12.1.0; Aperio Technologies) and the Positive Pixel Count algorithm with optimized color saturation thresholds. Any staining was considered positive and the number of positive pixels was divided by the total pixel count. Phospho-STAT-6 expression was assessed semiquantitatively in intrafollicular T cells.
Immunohistofluorescence on Stromal Cells
Mouse spleens and human lymph nodes were snap frozen in OCT (Tissue-Tek OCT Compound). Twenty-micrometer sections were fixed in 4% PFA for 15min at room temperature. Sections were incubated for 1 hr with a blocking solution (PBS, 10% BSA, 10% Donkey serum, 0.1% Saponin) then incubated in a humidified chamber overnight at 4 C with the following primary antibodies: CD21/CD35 (Rat IgG2b, dilution 1/50, BD Biosciences) and collagen I (Rabbit polyclonal, dilution 1/100, Abcam) for mouse spleens; and CD21L (Mouse IgM, dilution 1/100, Dako), Transglutaminase-2 (Mouse IgG1, dilution 1/50, Abcam), and CD20 (Polyclonal Rabbit, dilution 1/50, Abacam) from human lymph nodes. After washes, slides were incubated with the corresponding secondary antibodies (Jackson ImmunoResearch) and were finally mounted in Mowiol antifade reagent containing SytoxBlue (dilution 1/500, Invitrogen) and analyzed by confocal microscopy on a SP8 (Leica Microsystems). ImageJ software was used for image analysis.
T FH Stimulation
Purified T FH were cultured in IMDM 10% FCS with or without anti-CD3 (0.6mg/mL) and anti-CD28 (0.6mg/mL, Pelicluster Sanquin) MAbs in the presence or not of solHVEM (10mg/mL). After 3 days of culture, the number of viable T FH was evaluated by flow cytometry using count beads (Flow Count, Beckman Coulter) and Topro-3 staining (Invitrogen). CXCL13 and IL-21 were quantified in culture supernatants by ELISA (R&D Systems) according to manufacturer's instructions.
Real-Time Quantitative PCR B and T cells were isolated from the spleens of mice using bead cell separation. Whole cell lysates were subject to either Pan T Cell Isolation Kit or the B Cell Isolation Kit (Miltenyl Biotec) and isolated subject to manufacturers instruction.
B and T FH samples were sorted before qRT-PCR by cell sorting using the Biomark system (Fluidigm). Total RNA was extracted from tumors, sorted T cells, and sorted B cells using QIAGEN RNA extraction kit. Reverse transcription was performed on 1 mg of total RNA using the M-MulV reverse transcriptase (New England BioLabs). qRT-PCR analysis was performed by the DDCt method using TaqMan Universal master mix on an ABI Prism 7000 Sequence Detection System (Applied Biosystems) (Mavrakis et al., 2008) . Taqman Gene Expression assays were all received from Applied Biosystems: Gusb, HVEM, BTLA, LTa, TNFa, LTb, CCL19, CXCL13 .
Flow Cytometry
Single cell suspensions of each tumor genotype were obtained from mechanical dissociation and stained with representative surface maker antibody. After mechanical dissociation cells were collected in PBS-1%BSA and passed through a cell strainer to eliminate clumps and debris. Cells were spun down, suspended, and counted before primary antibody staining. Cells were stained with primary antibodies for at least 30 min on ice in the dark. After staining cells were washed twice with PBS-1%BSA and analyzed on a BD LSRFortessa (Becton Dickinson, Franklin Lakes, NJ) Antibodies used in staining from BD Biosciences: B220 (clone RA3-6B2), CD19 (clone 1D3), FAS (clone Jo2), T and B cell activation antigen (GL7), IgG (A85-1), IgM (R6-60.2), CD3 (clone 17A2), or Biolegend: HVEM (clone HMHV-1B18), BTLA (clone 6A6).
Phospho-Flow Cytometry
Purified IgG pos FL B cells were stimulated using FITC-conjugated goat anti-human IgG (Invitrogen, 10 m g/mL) in the presence of H 2 O 2
Sequencing of VDJ regions RNA was prepared from potentially tumoral lymphoid tissues and from a normal mouse spleen as control. Concentrations of RNA were confirmed using a nanodrop and $200ng RNA was used for sequencing. Transcripts were amplified using RACE-PCR starting with a reverse primer hybridizing within the m CH1 exon. Expressed VDJ regions from m heavy chain transcripts were sequenced through a next generation method. This strategy (Li et al., 2013) combined 5 0 RACE PCR, pyrosequencing and precise repertoire analysis with quantification of the most frequent clonotypes using IMGT/High-V-QuestmRNA and associated tools available on IMGT (the International ImMunoGeneTics information website (http://www.imgt.org/).
Cell Culture and Proliferation Assays
Lymphoma cell lines DoHH2, Ly-10, Granta, Su-DHL-6, Su-DHL-4, Su-DHL-10, Su-DHL-8, Raji were obtained from ATCC, authenticated, and maintained in RPMI-1640 with 10% fetal bovine serum, 1% L-Glutamine and 1% penicillin/streptomycin (Oricchio et al., 2014) . Mouse lymphoma cell line Myc/Bcl2 was maintained in IMDM-DMEM (50:50) with 10% fetal bovine serum, 1% L -Glutamine, and 1% penicillin/streptomycin. Bcl1 cell line was maintained in RPMI-1640 with 15% fetal bovine serum, 1% L-Glutamine and 1% penicillin/streptomycin, 0.05mM ME. Cell lines were seeded at 5 3 10 5 /mL and were treated with 10 mg/ml of sHVEM. After 24 hr cell number was counted using a hemocytometer for a total of 72 hr after treatment.
Treatment Studies
Transplant and treatment studies were generated as previously described (Schatz et al., 2011) (Pegram et al., 2012 ) was used as a control CAR. Tumors were measured after the animals were sacrificed and tumors excised 4 weeks after the CAR-T cell injection.
CAR-T Cell Generation
SFG-1928z vector was modified to contain GFP and the human extracellular HVEM sequence by addition of P2A site followed by IgG Kappa secretion signal that precedes HVEM (P37-V202) sequence. Green fluorescent protein (GFP) sequence was included as a leader peptide following 1828z sequence by addition of internal ribosomal entry site (IRES). Human T cells were isolated from human PBMCs by density centrifugation, and activated and expanded by culturing with CD3/CD28 Dynobeads (Invitrogen) in presence of IL-2 (Peprotech) and phytohemagglutinin (Sigma). Transduction of T cells was performed on rectronectin (Takara) covered plates. Upon T cell transduction, GFP+ cells were sorted and further expanded using CD3/CD28 beads. The cytolytic capacity of transduced T cells was determined by co-culturing target and effector cells at particular cell ratios (Pegram et al., 2012) . After 24 hr of co-culture, cells were harvested and stained for DAPI and Annexin V and assayed by flow cytometry to detect residual GFP-negative viable cells. HVEM expression was assessed via Western blot analysis of T cells containing 1928-GFP construct alone in comparison to T cells containing 1928-GFP-HVEM construct. HVEM secretion was confirmed by ELISA assay of cell culture supernatant using the Origene Human HVEM ELISA kit.
QUANTIFICATION AND STATISTICAL ANALYSIS Statistical Methods
Sample sizes for comparisons between cell types or between mouse genotypes followed Mead's recommendations (Festing and Altman, 2002) . Samples were allocated to their experimental groups according to their pre-determined type (i.e mouse genotype) and therefore there was no randomization. Investigators were not blinded to the experimental groups. Quantitative PCR data were obtained from independent biological replicates (n values indicated in the corresponding figure legends). Normal distribution and equal variance was confirmed in the large majority of data and, therefore, we assumed normality and equal variance for all samples. Based on this, we used the Student's t test (two-tailed, unpaired) or ANOVA where appropriate to estimate statistical significance. Survival in mouse experiments was represented with Kaplan-Meier curves, and significance was estimated with the log-rank test. For association analysis between HVEM and BTLA expression in human FL tissue biopsies we performed a Chi-square test. Statistical parameters including the exact value of n and statistical significance are reported in the Results, Figures and Figure Legends . Statistical analysis was performed using Graph Pad PRISM 6.
DATA AND SOFTWARE AVAILABILITY
The accession number for the raw data files reported in this paper is NCBI GEO: GSE40989.
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